Ceftazidime Pregnancy and Breastfeeding Warnings

Brand names: Ceptaz, Fortaz, Tazicef, Tazicef Novaplus, Tazidime

Medically reviewed by Drugs.com. Last updated on Aug 2, 2023.

Ceftazidime Pregnancy Warnings

Animal studies have failed to reveal evidence of embryolethality, fetolethality, fetal harm, impaired fertility, or teratogenicity at doses up to 40 times the human dose. There are no controlled data in human pregnancy.

AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

AU TGA pregnancy category: B1
US FDA pregnancy category: B

Comment: Use of adequate methods of contraception should be encouraged.

See references

Ceftazidime Breastfeeding Warnings

Use is generally considered acceptable; benefit to mother should outweigh risk to the infant.

Excreted into human milk: Yes

Comments:
-The American Academy of Pediatrics considers this drug as compatible with breastfeeding.
-Maternal doses of cephalosporins have resulted in reports of neonatal diarrhea and thrush.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer